{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T02:03:24Z","timestamp":1760061804405},"reference-count":6,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2002,9,1]],"date-time":"2002-09-01T00:00:00Z","timestamp":1030838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[2002,9]]},"DOI":"10.1006\/biol.2002.0340","type":"journal-article","created":{"date-parts":[[2002,10,8]],"date-time":"2002-10-08T07:07:34Z","timestamp":1034060854000},"page":"255-257","source":"Crossref","is-referenced-by-count":2,"title":["Effect of Sample Storage Conditions on Virus Inactivation by Solvent\/Detergent"],"prefix":"10.1006","volume":"30","author":[{"given":"Peter","family":"Roberts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1006\/biol.2002.0340_RF1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/(SICI)1099-1654(199603)6:1<25::AID-RMV162>3.0.CO;2-2","article-title":"Virus safety of plasma products","volume":"6","author":"Roberts","year":"1996","journal-title":"Rev Med Vir"},{"key":"10.1006\/biol.2002.0340_RF2","unstructured":"Committee for Proprietary Medicinal Products, European Medicines Evaluation Agency, Note for guidance on virus validation studies. The design, contribution and interpretation of studies validating the inactivation and removal of viruses, CPMP\/BWP\/268\/95, 1996"},{"key":"10.1006\/biol.2002.0340_RF3","series-title":"Virological Safety Aspects of Plasma Derivatives","first-page":"147","article-title":"Virus safety of solvent-detergent treated blood products","author":"Horowitz","year":"1993"},{"key":"10.1006\/biol.2002.0340_RF4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2516.1995.tb00095.x","article-title":"Development and characterisation of the high-purity factor IX, Replenine","volume":"1","author":"Feldman","year":"1995","journal-title":"Haemophilia"},{"key":"10.1006\/biol.2002.0340_RF5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/biol.1999.0236","article-title":"Resistance of vaccinia virus to inactivation by solvent\/detergent treatment of blood products","volume":"28","author":"Roberts","year":"2000","journal-title":"Biological"},{"key":"10.1006\/biol.2002.0340_RF6","first-page":"1163","article-title":"Virus inactivation during severe heat-treatment of a lyophilised factor VIII concentrate","volume":"65","author":"Roberts","year":"1991","journal-title":"Thromb Haemost"}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105602903404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105602903404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T16:50:04Z","timestamp":1554828604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1045105602903404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,9]]}},"alternative-id":["S1045105602903404"],"URL":"https:\/\/doi.org\/10.1006\/biol.2002.0340","relation":{},"ISSN":["1045-1056"],"issn-type":[{"value":"1045-1056","type":"print"}],"subject":[],"published":{"date-parts":[[2002,9]]}}}